JP2020512276A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512276A5
JP2020512276A5 JP2019527831A JP2019527831A JP2020512276A5 JP 2020512276 A5 JP2020512276 A5 JP 2020512276A5 JP 2019527831 A JP2019527831 A JP 2019527831A JP 2019527831 A JP2019527831 A JP 2019527831A JP 2020512276 A5 JP2020512276 A5 JP 2020512276A5
Authority
JP
Japan
Prior art keywords
carbon atoms
branched
substituted
linear
cyclic alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019527831A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512276A (ja
JP7203729B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/062989 external-priority patent/WO2018098258A2/en
Publication of JP2020512276A publication Critical patent/JP2020512276A/ja
Publication of JP2020512276A5 publication Critical patent/JP2020512276A5/ja
Priority to JP2022207896A priority Critical patent/JP2023036842A/ja
Application granted granted Critical
Publication of JP7203729B2 publication Critical patent/JP7203729B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019527831A 2016-11-23 2017-11-22 ベンゾジアゼピン誘導体の選択的スルホン化 Active JP7203729B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022207896A JP2023036842A (ja) 2016-11-23 2022-12-26 ベンゾジアゼピン誘導体の選択的スルホン化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662425761P 2016-11-23 2016-11-23
US62/425,761 2016-11-23
PCT/US2017/062989 WO2018098258A2 (en) 2016-11-23 2017-11-22 Selective sulfonation of benzodiazepine derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022207896A Division JP2023036842A (ja) 2016-11-23 2022-12-26 ベンゾジアゼピン誘導体の選択的スルホン化

Publications (3)

Publication Number Publication Date
JP2020512276A JP2020512276A (ja) 2020-04-23
JP2020512276A5 true JP2020512276A5 (https=) 2021-01-07
JP7203729B2 JP7203729B2 (ja) 2023-01-13

Family

ID=60655118

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019527831A Active JP7203729B2 (ja) 2016-11-23 2017-11-22 ベンゾジアゼピン誘導体の選択的スルホン化
JP2022207896A Pending JP2023036842A (ja) 2016-11-23 2022-12-26 ベンゾジアゼピン誘導体の選択的スルホン化

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022207896A Pending JP2023036842A (ja) 2016-11-23 2022-12-26 ベンゾジアゼピン誘導体の選択的スルホン化

Country Status (11)

Country Link
US (5) US10287256B2 (https=)
EP (1) EP3544983A2 (https=)
JP (2) JP7203729B2 (https=)
KR (2) KR20230133935A (https=)
CN (2) CN110392685B (https=)
AU (2) AU2017363237B2 (https=)
CA (1) CA3044391A1 (https=)
IL (2) IL266743B (https=)
MA (1) MA46887A (https=)
TW (2) TWI845890B (https=)
WO (1) WO2018098258A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3769787A1 (en) * 2015-06-29 2021-01-27 ImmunoGen, Inc. Conjugates of cysteine engineered antibodies
ES2887273T3 (es) 2015-06-29 2021-12-22 Immunogen Inc Anticuerpos anti-CD123 y conjugados y derivados de los mismos
TWI845890B (zh) * 2016-11-23 2024-06-21 美商伊繆諾金公司 苯二氮平衍生物之選擇性磺化
US20200157228A1 (en) * 2018-10-30 2020-05-21 Immunogen, Inc. Methods of treatment using anti-cd123 immunoconjugates
WO2020092344A1 (en) * 2018-10-31 2020-05-07 Health Research, Inc. Combination treatment with anti-cd123 antibody drug conjugate and parp inhibitor
US11833214B2 (en) 2019-03-21 2023-12-05 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
CA3137454A1 (en) 2019-04-29 2020-11-05 Immunogen, Inc. Therapeutic combinations comprising anti-cd123 immunoconjugates
US20220306751A1 (en) 2019-09-13 2022-09-29 Mythic Therapeutics, Inc. Antigen-binding protein constructs and uses thereof
CN113189184B (zh) * 2021-04-28 2022-09-09 浙江大学 含有半胱氨酸的毛细管凝胶电泳样品缓冲液
KR20250031149A (ko) 2022-06-30 2025-03-06 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2149768T3 (es) 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
ES2276708T3 (es) 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
CN100522955C (zh) 2002-08-02 2009-08-05 伊缪诺金公司 含有新型强效紫杉烷的细胞毒性剂及其治疗用途
JP2006500364A (ja) 2002-08-16 2006-01-05 イムノージェン インコーポレーテッド 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用
BR0316101A (pt) 2002-11-07 2005-09-27 Immunogen Inc Anticorpos anticd33 e processo para tratamento de leucemia melóide aguda usando os mesmos
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
AU2005218642B2 (en) 2004-03-02 2011-04-28 Seagen Inc. Partially loaded antibodies and methods of their conjugation
KR20120064120A (ko) 2004-06-01 2012-06-18 제넨테크, 인크. 항체 약물 접합체 및 방법
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
EP1817341A2 (en) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
PL1879901T3 (pl) 2005-04-21 2010-06-30 Medimmune Ltd Pirolobenzodiazepiny
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
ES2567402T3 (es) 2006-05-30 2016-04-22 Genentech, Inc. Anticuerpos anti CD22, sus inmunoconjugados y usos de los mismos
WO2008119353A1 (en) 2007-03-29 2008-10-09 Genmab A/S Bispecific antibodies and methods for production thereof
PL2019104T3 (pl) 2007-07-19 2014-03-31 Sanofi Sa Środki cytotoksyczne obejmujące nowe pochodne tomaymycyny i ich zastosowanie terapeutyczne
KR20200058590A (ko) 2008-04-30 2020-05-27 이뮤노젠 아이엔씨 가교제 및 그 용도
EP2276506A4 (en) 2008-04-30 2014-05-07 Immunogen Inc EFFICIENT CONJUGATES AND HYDROPHILIC BINDER
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
CN102365021B (zh) 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
AU2010270979B2 (en) 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
WO2011092838A1 (ja) 2010-01-29 2011-08-04 株式会社フォーサイド・ドット・コム コンテンツ共有システム、およびコンテンツ共有方法
CN103037900B (zh) 2010-02-24 2016-04-06 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
SG183542A1 (en) 2010-03-12 2012-10-30 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
US8697688B2 (en) 2010-04-15 2014-04-15 Seattle Genetics Inc. Pyrrolobenzodiazepines used to treat proliferative diseases
DK2560993T3 (da) 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
CN103298489A (zh) 2010-10-29 2013-09-11 伊缪诺金公司 新型egfr结合分子及其免疫偶联物
CN105399831A (zh) 2010-10-29 2016-03-16 伊缪诺金公司 非拮抗性egfr结合分子及其免疫偶联物
JP6049642B2 (ja) 2011-02-15 2016-12-21 イミュノジェン・インコーポレーテッド 複合体の調製方法
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
JP6494533B2 (ja) 2013-02-28 2019-04-03 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体
WO2014134457A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014134486A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
CN115124573A (zh) * 2013-09-02 2022-09-30 杭州多禧生物科技有限公司 应用于细胞结合分子-药物共轭体的新型细胞毒性分子
WO2015196089A1 (en) 2014-06-20 2015-12-23 Bioalliance C.V. Anti-cd22 antibody-drug conjugates and methods of using thereof
SG11201610620UA (en) 2014-06-20 2017-01-27 Bioalliance Cv Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof
CN106999604B (zh) 2014-09-02 2021-08-03 伊缪诺金公司 用于配制抗体药物缀合物组合物的方法
EP3189057A1 (en) 2014-09-03 2017-07-12 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
ES2815353T3 (es) * 2014-09-03 2021-03-29 Immunogen Inc Derivados de benzodiazepina citotóxicos
MA41645A (fr) 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
ES2887273T3 (es) 2015-06-29 2021-12-22 Immunogen Inc Anticuerpos anti-CD123 y conjugados y derivados de los mismos
EP3769787A1 (en) 2015-06-29 2021-01-27 ImmunoGen, Inc. Conjugates of cysteine engineered antibodies
MX2018009487A (es) 2016-02-05 2019-01-31 Millennium Pharm Inc Conjugados de anticuerpo y fármaco dirigidos contra gcc.
TWI845890B (zh) 2016-11-23 2024-06-21 美商伊繆諾金公司 苯二氮平衍生物之選擇性磺化

Similar Documents

Publication Publication Date Title
JP2020512276A5 (https=)
CN111848615B (zh) 吡啶酮衍生物及包含其的抗流感病毒药物组合物
US8609857B2 (en) Poly(ethylene glycol) containing chemically disparate endgroups
PH12015500758B1 (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
JP2014506892A5 (https=)
WO2016014522A1 (en) Inhibitors of deubiquitinating proteases
ES2752552T3 (es) Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa
JP2022541749A (ja) 治療薬としての細胞毒素のペプチドコンジュゲート
EP3078699B1 (en) Multi-arm polyethylene glycol-nitrine derivative
JP2007511527A5 (https=)
CA2635482A1 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
ES2475721T3 (es) Síntesis de un piperazina neuroestimulante
CA2402092A1 (en) 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
ES2635117T3 (es) Método para la fabricación de un copolímero de bloques
JP2006508147A5 (https=)
ES2879294T3 (es) Formas polimórficas de Belinostat y procesos para la preparación de las mismas
MX2007007830A (es) Compuestos de piridina para el tratamiento de enfermedades mediadas por prostaglandina.
JPWO2019213445A5 (https=)
CN104861161A (zh) 一种制备端氨基聚乙二醇的方法
CN102137867A (zh) 水鬼蕉碱的氮化衍生物
JP2021505537A5 (https=)
ES2349372T3 (es) Derivados de talidomina solubles en agua.
JP2006502086A5 (https=)
ES2923932T3 (es) Un procedimiento mejorado para la preparación de rivaroxabán que implica un intermedio novedoso
ES2547697T3 (es) Atropisómeros de (hidroxialquil)pirrol derivados